Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo's injectable blockbuster.
Nick Paul Taylor
Apr 17, 2025 6:45am
Dexcom survey shows providers opt for tech over drugs in Type 2
Mar 19, 2025 12:20pm
FDA clears Tandem Diabetes insulin-dosing algorithm in Type 2
Feb 25, 2025 2:01pm
Fractyl pivots T2D therapy to obesity & GLP-1s, lays off staff
Jan 31, 2025 11:45am
Novo bets $190M near-term on AI pact in obesity, diabetes
Jan 8, 2025 8:00am
Biomea's diabetes drug improves glucose control in ph. 2 trial
Dec 17, 2024 9:50am
